Share on StockTwits

A number of stock research firms have changed their ratings and price targets for AstraZeneca plc (LON: AZN) during the last seven days:

  • AstraZeneca plc had its “underweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 3,700 ($61.85) price target on the stock.
  • AstraZeneca plc had its “hold” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 4,500 ($75.23) price target on the stock.
  • AstraZeneca plc had its “sell” rating reaffirmed by analysts at Societe Generale. They now have a GBX 3,700 ($61.85) price target on the stock.
  • AstraZeneca plc had its “neutral” rating reaffirmed by analysts at Credit Suisse. They now have a GBX 4,800 ($80.24) price target on the stock.

AstraZeneca plc (LON:AZN) traded up 2.54% during mid-day trading on Monday, hitting GBX 4196.50. 1,608,468 shares of the company’s stock traded hands. AstraZeneca plc has a 1-year low of GBX 3086.50 and a 1-year high of GBX 5750.00. The stock has a 50-day moving average of GBX 4320.81 and a 200-day moving average of GBX 4193.89. The company’s market cap is £53.002 billion.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.